MacroGenics Inc - ESG Rating & Company Profile powered by AI
This Sustainability rating for MacroGenics Inc indicates the company's transparency towards the United Nations Sustainable Development Goals. The webpage contains a zero-cost Sustainability analysis covering MacroGenics Inc. Browse to the bottom of the webpage for potential risks for MacroGenics Inc based on sector, geography and marketcap.
MacroGenics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.3; made up of an environmental score of 6.0, social score of 6.4 and governance score of 6.4.
6.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 402 | United Laboratories International Holdings Ltd | 6.4 | High |
| 402 | Zenabis Global Inc | 6.4 | High |
| 427 | MacroGenics Inc | 6.3 | High |
| 427 | Calliditas Therapeutics AB | 6.3 | High |
| 427 | Carna Biosciences Inc | 6.3 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does MacroGenics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes MacroGenics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes MacroGenics Inc report the average age of the workforce?
Sign up for free to unlockDoes MacroGenics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes MacroGenics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes MacroGenics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes MacroGenics Inc offer flexible work?
Sign up for free to unlockDoes MacroGenics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes MacroGenics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes MacroGenics Inc conduct supply chain audits?
Sign up for free to unlockDoes MacroGenics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes MacroGenics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes MacroGenics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes MacroGenics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes MacroGenics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes MacroGenics Inc disclose water use targets?
Sign up for free to unlockDoes MacroGenics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid MacroGenics Inc have a product recall in the last two years?
Sign up for free to unlockDoes MacroGenics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes MacroGenics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas MacroGenics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes MacroGenics Inc disclose parental leave metrics?
Sign up for free to unlockDoes MacroGenics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes MacroGenics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes MacroGenics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes MacroGenics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes MacroGenics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes MacroGenics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs MacroGenics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes MacroGenics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes MacroGenics Inc disclose its waste policy?
Sign up for free to unlockDoes MacroGenics Inc report according to TCFD requirements?
Sign up for free to unlockDoes MacroGenics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes MacroGenics Inc disclose energy use targets?
Sign up for free to unlockDoes MacroGenics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes MacroGenics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for MacroGenics Inc
These potential risks are based on the size, segment and geographies of the company.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.